Endothelin type A receptor blockade increases renoprotection in congestive heart failure combined with chronic kidney disease: Studies in 5/6 nephrectomized rats with aorto-caval fistula - 13/01/23
, Zdenka Vaňourková b, Petra Škaroupková b, Elżbieta Kompanowska-Jezierska c, Janusz Sadowski c, Agnieszka Walkowska c, Josef Veselka a, Miloš Táborský d, Hana Maxová e, Ivana Vaněčková f, Luděk Červenka b, dAbstract |
Background |
Association of congestive heart failure (CHF) and chronic kidney disease (CKD) worsens the patient’s prognosis and results in poor survival rate. The aim of this study was to examine if addition of endothelin type A (ETA) receptor antagonist to the angiotensin-converting enzyme inhibitor (ACEi) will bring additional beneficial effects in experimental rats.
Methods |
CKD was induced by 5/6 renal mass reduction (5/6 NX) and CHF was elicited by volume overload achieved by creation of aorto-caval fistula (ACF). The follow-up was 24 weeks after the first intervention (5/6 NX). The treatment regimens were initiated 6 weeks after 5/6 NX and 2 weeks after ACF creation.
Results |
The final survival in untreated group was 15%. The treatment with ETA receptor antagonist alone or ACEi alone and the combined treatment improved the survival rate to 64%, 71% and 75%, respectively, however, the difference between the combination and either single treatment regimen was not significant. The combined treatment exerted best renoprotection, causing additional reduction in albuminuria and reducing renal glomerular and tubulointerstitial injury as compared with ACE inhibition alone.
Conclusions |
Our results show that treatment with ETA receptor antagonist attenuates the CKD- and CHF-related mortality, and addition of ETA receptor antagonist to the standard blockade of RAS by ACEi exhibits additional renoprotective actions.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Keywords : Congestive heart failure, Chronic kidney disease, Endothelin system, Endothelin receptor type A, Aorto-caval fistula, 5/6 nephrectomy
Plan
Vol 158
Article 114157- février 2023 Retour au numéro
Article précédent
- IRGM/Irgm1 deficiency inhibits neutrophil-platelet interactions and thrombosis in experimental atherosclerosis and arterial injury
- Song Sun, Xiaoyi Zou, Duo Wang, Yige Liu, Zhenming Zhang, Junchen Guo, Rongzhe Lu, Wei Huang, Shanjie Wang, Zhaoying Li, Jiangtian Tian, Huai Yu, Jin Fu, Shaohong Fang
- Health-related quality of life and productivity costs in breast cancer patients treated with tamoxifen in the Netherlands
- Anne Kleijburg, C. Louwrens Braal, Justin D. Westenberg, Agnes Jager, Stijn L.W. Koolen, Ron H.J. Mathijssen, Carin A. Uyl-de Groot, Pim Wetzelaer, Hannah Penton
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?